GRGopalkumar Rakesh

Gopalkumar Rakesh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gopalkumar Rakesh has a total of 165 co-authors. Here are the top co-authors by number of shared publications:

  • Craig R. Rush

    Department of Psychiatry, College of Medicine, University of Kentucky

    9 shared publications
  • Rebika Khanal

    Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia, USA

    9 shared publications
  • Seth S. Himelhoch

    Department of Psychiatry and Behavioral Sciences, University of Chicago, Illinois, USA

    8 shared publications
  • Thomas G. Adams

    6 shared publications
  • Rajendra A. Morey

    Department of Psychiatry, Duke University School of Medicine, Durham, North Carolina, USA

    5 shared publications
  • Dylan H. Ballard

    Department of Psychiatry, College of Medicine, University of Kentucky, Lexington, Kentucky, USA

    4 shared publications

Latest Publications

  • Open Access

    Unbundling Transcranial Magnetic Stimulation (TMS) treatment protocols: Standardized reporting for component controlled trials

    by Austin R. Messner, Thomas G. Adams, Elizabeth M. Arnold, Gopalkumar Rakesh

  • Examining the Neural and Behavioral Impact of Accelerated Intermittent Theta Burst Stimulation in People with Opioid Use Disorder Who Smoke Tobacco Cigarettes: A Pilot Study

    by Dylan H. Ballard, Thomas G. Adams, Rajendra A. Morey, Rebika Khanal, Seth S. Himelhoch, Gopalkumar Rakesh

    Background: Novel therapies are needed to improve smoking cessation outcomes in people with opioid use disorder (OUD), as they are far more likely to smoke cigarettes (70–90%) compared to the general population (11.6%) and demonstrate a poorer response to smoking cessation interventions. Methods: This pilot study, intended to be a hypothesis-generating mechanistic investigation, is the first to explore the impact of a single day (four sessions) of accelerated intermittent theta burst stimulation (iTBS) (1800 pulses/session) versus sham iTBS applied to the left dorsolateral prefrontal cortex (L-dlPFC) in people with OUD who smoke tobacco cigarettes ( n = 8 received iTBS, n = 7 received sham iTBS). Resting-state functional connectivity was acquired at baseline and after the fourth session. Attentional bias for cigarette and opioid cues, and craving assessments, were completed at baseline, and after the first and fourth sessions. Results: Connectivity between the L-dlPFC seed and a cluster comprising the left anterior supramarginal gyrus showed a significant group × time interaction, with planned comparisons showing a greater increase at follow-up in the iTBS compared with sham iTBS group ( t 12 = 6.37, β = 0.40, p < 0.001). Cigarette cue attentional bias showed a significant group × session interaction ( t 80 = 2.34 , p = 0.02), with planned comparisons showing a decrease after iTBS and an increase following sham iTBS. No effect of iTBS was observed for opioid cue attentional bias. Cigarette craving decreased in both iTBS and sham groups but did not show a significant group × session interaction. Conclusions: These results are promising but should be interpreted with caution, given the limited sample size, which precluded analyses adjusting for sex or medications for OUD. This pilot study aims to identify neural and behavioral targets for future studies of accelerated iTBS in people with OUD who smoke cigarettes. Future trials could examine the effects of increased doses of iTBS (e.g., more days of accelerated iTBS) to identify dosing to promote smoking cessation among individuals with OUD effectively.


  • Transcranial Magnetic Stimulation (TMS) for Smoking Cessation in Cancer Survivors: A Path Forward

    by Gopalkumar Rakesh, Tia N. Weber, Hamed Ekhtiari, Jessica L. Burris

    Cigarette smoking after a cancer diagnosis is associated with increased mortality, cancer recurrence, treatment-related toxicity, and diminished quality of life, yet sustained cessation remains a challenge. Transcranial magnetic stimulation (TMS), an FDA-approved noninvasive neuromodulation treatment for both major depressive disorder and smoking cessation, represents a promising intervention for cancer survivors due to its unique multitarget effects. Cancer survivors experience high rates of comorbid psychopathology, including depression, anxiety, suicidal ideation, and pain—conditions that interact with smoking behaviors and for which TMS has demonstrated efficacy. However, the current standardized TMS protocol for smoking cessation requires adaptation for cancer populations, given their unique clinical needs. This paper proposes a stakeholder-engaged adaptation framework involving cancer survivors, oncology clinicians, tobacco treatment specialists, TMS psychiatrists, and other key stakeholders to systematically adapt TMS protocols for cancer survivors. We discuss a roadmap for procedural adaptation prior to efficacy trials, including flexible dosing schedules and accelerated protocols, secondary outcome measures beyond smoking behaviors, implementation considerations for integration into oncology care settings, and anticipated barriers and potential solutions. This framework provides a roadmap for developing an optimized, equitable TMS intervention to improve smoking cessation outcomes in cancer survivors.

  • Open Access

    Pharmacological Smoking Cessation Interventions in People with Cannabis, Opioid, or Stimulant Use Disorders: A Systematic Review

    by Nicole Brar, Bs Imamhulhaq Brula, Dylan H Ballard, Brittany Musselwhite, Gopalkumar Rakesh

    Introduction . Tobacco use disorder (TUD) is highly prevalent among people with cannabis use disorder (CUD), opioid use disorder (OUD), and stimulant use disorder (StUD), encompassing cocaine use disorder and methamphetamine use disorder. TUD increases the severity of other substance use disorders and leads to increased incidence of health complications, resulting in elevated mortality. We reviewed studies that examined the impact of approved pharmacological smoking cessation strategies, either alone or in combination with behavioral interventions, in people with CUD, OUD, and StUD who smoke tobacco cigarettes. Methods . We registered the systematic review on PROSPERO (CRD42023467758). We searched three databases (PubMed/Medline, Google Scholar, and EMBASE) using specific MeSH terms to identify human clinical trials published in English between January 1 st , 2000, and September 30th, 2024. Results . We selected 27 eligible studies, encompassing 1) CUD (n=7); 2) OUD (n=15); and 3) StUD (n=5). Approved pharmacological smoking cessation interventions, such as nicotine replacement therapy (NRT), varenicline, and bupropion, demonstrated poor efficacy in CUD, OUD, and StUD. We identified just four placebo-controlled trials for varenicline (1 in CUD, 2 in OUD, and 1 in StUD). Varenicline showed the most promise in StUD, short-term benefit in CUD, and, paradoxically, no benefit over placebo in two well-controlled OUD trials. Just four studies performed the recommended biochemical verification using both exhaled carbon monoxide (CO) and urine cotinine. Conclusions . Across the three disorders, pharmacological smoking cessation interventions demonstrated poor efficacy. More importantly, these conclusions were drawn from a sparse number of studies. Outcome measures were inconsistent across studies. Implications . This systematic review reveals a profound evidence gap in smoking cessation treatment for individuals with CUD, OUD, or StUD. Across 27 included studies, we identified only four placebo-controlled varenicline trials combined across all three disorders, in stark contrast to 33 such trials in general populations. The limited available evidence suggests approved pharmacological interventions demonstrate suboptimal and variable efficacy compared to the general population. Varenicline showed the most promise in StUD, short-term benefit in CUD, and no clear benefit in two placebo-controlled OUD trials. Bupropion demonstrated efficacy in StUD but limited evidence in other disorders. Combination pharmacotherapy remains almost completely unstudied in these populations. Most studies followed participants for 12 weeks or less, providing little information about sustained long-term abstinence. Current clinical practice guidelines offer insufficient disorder-specific guidance and do not acknowledge the apparent differential treatment responses across specific disorders. Urgent research priorities include: (1) adequately powered, placebo-controlled trials of single and combination pharmacotherapies with extended follow-up; (2) investigate novel interventions such as cytisine, digital therapeutics, and TMS; (3) and develop disorder-specific treatment approaches.

  • Theta Burst Stimulation With Facial Titanium Implants

    by Imamulhaq Brula, Elizabeth Mayfield Arnold, Gopalkumar Rakesh

  • Open Access

    Repetitive Transcranial Magnetic Stimulation in Substance Use Disorders is Safe and Tolerable: A Systematic Review of 141 Clinical Trials Including 4,299 Participants

    by Afra Souki, Shermin Sharifzadeh, Kathleen Brady, Colleen A Hanlon, Manish Kumar Jha, Kelvin O Lim, Gopalkumar Rakesh, Jonathan R Young, Vaughn R Steele, Victor M Tang, et al.

    Background Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive neuromodulation intervention that has been investigated as a treatment for substance use disorder (SUD) and its co-occurring disorders. As the number of rTMS SUD clinical trials increase, the safety and tolerability profile should be assessed. In this systematic review, we investigate adverse events (AEs) of rTMS in individuals with SUD and factors that may influence their occurrence, including treatment status, and substance-use type. Methods We performed a systematic PubMed search to identify all controlled trials of rTMS in SUD published up to January 2025. Eligible studies were assessed, and safety information was extracted for analysis. Results A total of 141 controlled clinical trials with 4,299 participants were included in their active arms. rTMS trials recruited participants who were engaged in active substance use (37 studies), in the pre-treatment phase (61), in early recovery (18), or in sustained recovery (25). Twenty-two studies (15.60 %) explicitly reported no AEs adverse effects. Sixty-nine (48.94 %) studies reported only mild AEs adverse events, while only six studies (4.26%) reported moderate AEs adverse events. Thirty-five studies did not report safety-outcomes/AEs. As expected, participants reported mild and temporary AEs such as headaches, pain or discomfort under the coil, or dizziness. The most frequent side effects were headache (57 studies in active TMS vs. 32 in sham TMS), pain or discomfort at the stimulation site (34 vs. 20 studies), and dizziness (11 vs. 5 studies). These effects were generally temporary and did not require participants to stop treatment. Only nine studies reported serious side effects (7 studies in active TMS and 2 in sham TMS). Importantly, no seizures attributable to active rTMS were reported in these SUD samples. The other severe events included severe headache (5 studies), tinnitus (1), disorientation (1), and suicidal ideation (1). In total, 9 studies reported dropout due to adverse effects. Thirty-five studies (24.82%) did not report safety-outcomes/adverse-events. Conclusion Overall, rTMS in SUD samples is safe and well-tolerated regardless of recovery stage and substance. Most reported side effects were mild, self-limiting, and tolerable. This evidence supports the safety of rTMS as a potential stand-alone or adjunctive treatment for SUD. Highlights We reviewed 141 controlled rTMS trials with 4,299 SUD participants rTMS in SUDs is safe and well-tolerated No reports of rTMS-induced seizures among 4,299 participants Most side-effects were mild and transient (headache, scalp pain) Standardized reporting of side-effects and adverse events is needed

  • Open Access

    Examining the Neural and Behavioral Impact of Accelerated Intermittent Theta Burst Stimulation (iTBS) in People with Opioid Use Disorder (OUD) Who Smoke Tobacco Cigarettes: A Pilot Study

    by Dylan H. Ballard, Thomas G. Adams, Rajendra A. Morey, Rebika Khanal, Seth S. Himelhoch, Gopalkumar Rakesh

    Novel therapies are needed to improve smoking cessation outcomes in people with opioid use disorder (OUD), as they are far more likely to smoke cigarettes (70-90%) compared to the general population (11.6%) and demonstrate poorer response to smoking cessation interventions. This pilot study was the first to explore the impact of a single day (four sessions) of accelerated intermittent theta burst stimulation (iTBS) (1800 pulses/session) versus sham iTBS on the left dorsolateral prefrontal cortex (L.dlPFC) in people with OUD who smoke tobacco cigarettes (n=8 received iTBS, n=7 received sham iTBS). Resting state functional connectivity (rsFC) was acquired at baseline and after the fourth session. Attentional bias for cigarette and opioid cues, and craving assessments were completed at baseline, and after the first and fourth sessions. Connectivity between the L.dlPFC seed and a cluster comprising the left anterior supramarginal gyrus (SMG) showed a significant group × time interaction, with planned comparisons showing a greater increase at follow-up with iTBS compared to sham iTBS ( t 12 =6.37, beta =0.40, p t 82 =2.34 , p =0.02), with planned comparisons revealing a decrease after iTBS and an increase after sham iTBS. No effect of iTBS was observed for opioid cue attentional bias. Cigarette craving decreased with both iTBS and sham iTBS but did not show a significant group × session interaction. These results are promising but need to be interpreted with caution, given the limited sample size and multiple comparisons. Future trials could examine the effects of increased doses of iTBS (e.g., more days of accelerated iTBS) to identify the dosing required to promote smoking cessation among individuals with OUD effectively.


  • Theta burst stimulation (TBS) in methamphetamine use disorder: a meta-analysis and systematic review

    by Gopalkumar Rakesh, Thomas G. Adams, Dylan H. Ballard, Christopher J. McLouth, Craig R. Rush

    Methamphetamine use disorder (MUD) currently lacks FDA-approved treatments. Previous studies involving transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (L.dlPFC) have shown promise in TMS's effectiveness at decreasing craving for methamphetamine. Theta burst stimulation (TBS), which includes intermittent (iTBS) and continuous (cTBS) protocols, is increasingly being used for substance use disorders, including MUD. Previous reviews of TMS in MUD performed subgroup meta-analyses of studies that delivered TBS in MUD. However, these meta-analyses included studies with overlapping participant cohorts, limiting their validity. To address this limitation, we reviewed randomized controlled trials (RCTs) using unique patient cohorts from PubMed/Medline, EMBASE, and Google Scholar until September 1, 2024, comparing the impact of TBS versus sham on cue-induced methamphetamine craving in patients with MUD. We performed a meta-analysis with four eligible RCTs that delivered iTBS. Results suggest iTBS was more effective in reducing cue-induced methamphetamine craving than sham iTBS (standardized mean difference [SMD] in change = 1.04; 95% CI [0.16, 1.92]). Two additional RCTs without sham control arms were reviewed, and one demonstrated a significant reduction in craving following accelerated iTBS. Future studies should examine whether neuroimaging-targeted iTBS can impact outcome measures other than craving, such as methamphetamine use, by measuring return to use. Exploring accelerated iTBS and cTBS for MUD, targeting alternative cortical sites such as the frontal pole, and studying their effects on relevant MUD biomarkers is also pertinent. This review demonstrates the effectiveness of TBS for MUD, emphasizing its potential to advance treatment options for MUD.


  • Open Access

    Theta Burst Stimulation in Patients With Methamphetamine Use Disorder: A Meta-Analysis and Systematic Review

    by Gopalkumar Rakesh, Thomas G. Adams, Dylan H. Ballard, Christopher J. McLouth, Craig R. Rush

    Novel interventions are urgently needed to treat methamphetamine use disorder (MUD), for which there are no FDA-approved treatments. Previous studies in patients with MUD suggest transcranial magnetic stimulation (TMS) over the left dorsolateral prefrontal cortex (L. dlPFC) decreases craving for methamphetamine. Theta burst stimulation (TBS), which includes intermittent TBS and continuous TBS (cTBS), is increasingly being used for substance use disorders, including MUD. Previous reviews of TMS in MUD performed sub-group meta-analyses of studies that delivered TBS in MUD. However, these meta-analyses included studies with overlapping participant cohorts. Given the absence of prior meta-analyses or reviews examining TBS in MUD using unique participant cohorts, we reviewed randomized controlled trials (RCTs) from three databases (PubMed/Medline, EMBASE, Google Scholar) until September 1, 2024, comparing the impact of TBS versus sham TBS on cue-induced methamphetamine cravings in patients with MUD. We performed a meta-analysis with four eligible RCTs that delivered iTBS. Results suggest iTBS was more effective in reducing cue-induced methamphetamine cravings than sham iTBS (standardized mean difference [SMD] in change = 1.04; 95% CI [0.16, 1.92]). Our systematic review included two additional RCTs that did not have sham comparator arms; one of these demonstrated a significant reduction in methamphetamine craving with accelerated iTBS. Future studies should examine if iTBS can impact clinical outcome measures other than craving, such as methamphetamine use, by measuring return to drug use. It is also pertinent to explore accelerated iTBS and cTBS for MUD and study their effects on relevant biomarkers for MUD.

  • TMS for Opioid Use Disorder

    by Jeffrey Taylor Owen, Gopalkumar Rakesh, G. Randolph Jr Schrodt, Ali A. Farooqui